Zentalis Pharmaceuticals (ZNTL) Common Equity (2019 - 2026)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Common Equity of $182.7 million for Q1 2026, down 38.15% year-over-year from $295.4 million in Q1 2025, and down 15.51% quarter-over-quarter from $216.2 million in Q4 2025.
Zentalis Pharmaceuticals (ZNTL) Common Equity (2019 - 2026) Analysis & Trends
Zentalis Pharmaceuticals' Common Equity history runs 8 years deep, the most recent figure standing at $182.7 million for Q1 2026.
- In Q1 2026, Common Equity fell 38.15% year-over-year to $182.7 million; the TTM figure through Mar 2026 stood at $182.7 million (down 38.15% YoY), while the FY2025 annual figure was $216.2 million, down 35.88% from the prior year.
- Common Equity for Q1 2026 stood at $182.7 million, down from $216.2 million in the prior quarter.
- The five-year high for Common Equity was $523.3 million in Q2 2023, with the low at $182.7 million in Q1 2026.
- The 5-year median for Common Equity is $382.6 million (2024), against an average of $366.7 million.
- The sharpest annual moves came in 2022 and 2026: Common Equity surged 90.96% in 2022, then tumbled 38.15% in 2026.
- Zentalis Pharmaceuticals' Common Equity stood at $434.0 million in 2022, then gained by 0.78% to $437.4 million in 2023, then slipped by 22.91% to $337.2 million in 2024, then slumped by 35.88% to $216.2 million in 2025, then decreased by 15.51% to $182.7 million in 2026.
- Business Quant data shows ZNTL's Common Equity at $182.7 million in Q1 2026, $216.2 million in Q4 2025, and $252.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Zentalis Pharmaceuticals | 255.14 Mn | 255.14 Mn | - | 143.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 143.65 Mn |
| Mar 31, 2026 | 182.68 Mn |
| Dec 31, 2025 | 216.20 Mn |
| Sep 30, 2025 | 252.87 Mn |
| Jun 30, 2025 | 274.50 Mn |
| Mar 31, 2025 | 295.38 Mn |
| Dec 31, 2024 | 337.19 Mn |
| Sep 30, 2024 | 354.33 Mn |
| Jun 30, 2024 | 382.58 Mn |
| Mar 31, 2024 | 458.77 Mn |
| Dec 31, 2023 | 437.39 Mn |
| Sep 30, 2023 | 481.90 Mn |
| Jun 30, 2023 | 523.28 Mn |
| Mar 31, 2023 | 385.67 Mn |
| Dec 31, 2022 | 434.02 Mn |
| Sep 30, 2022 | 428.74 Mn |
| Jun 30, 2022 | 472.82 Mn |
| Mar 31, 2022 | 315.67 Mn |
| Dec 31, 2021 | 364.48 Mn |
| Sep 30, 2021 | 394.00 Mn |